Skip to main content
OpenTrials
Completed

NCT Number: NCT02603016

Efficacy Study of Clinical Nutrition to Treat Lung Neoplasms And Breast Carcinoma

This study evaluates the efficacy of clinical nutrition to treat lung neoplasms and breast carcinoma.We estimate there will be 480 patients accepted.120 patients will receive GLSE compound,120 patients will recrive Maitake mushroom extract compound,120 patients will recrive Rinseng compound,and 120 patients will be as blank countrol group.Efficacy Study of Clinical Nutrition to Treat Lung Neoplasms And Breast Carcinoma

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Lung Neoplasms Breast Diseases Breast Neoplasms Lung Diseases Neoplasms Neoplasms by Site Respiratory Tract Diseases Respiratory Tract Neoplasms Skin Diseases Skin and Connective Tissue Diseases Thoracic Neoplasms

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

PLA general hospital

Beijing, Beijing Municipality, 1000853, China

About this study

GLSE compound、Maitake mushroom extract compound and Rinseng compound have different mechanism on enhancing immunity.This clinicaltrial compare them the immune effect in the progress of treating lung neoplasms and breast carcinoma.Within the 42 days,we will abide by the plan to evaluate the immunity enhancement by monitoring mmune effector molecules.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • lung cancer and breast cancer patients confirmed by surgery pathology;
  • ECOG physical stamina score of 0~3 points;
  • Expected lifetime > 3 months;
  • Need to receive radiation and chemotherapy;
  • Heart, liver and kidney function and blood picture is normal,WBC≥4×109/L, neutrophil count≥ 2 x 109 / L,platelet count≥100×109/L, hemoglobin≥100 g/L;
  • To follow-up, good adherence

Exclusion criteria

  • Allergic to text drug;
  • Pregnancy or lactation women;
  • Suffering from mental illness of not easy to control,
  • Have serious mental or cognitive dysfunction;
  • Can not comply with the experimental scheme or can't cooperate with the follow-up;
  • The patients who are unfavorable to the subject.

Treatment and study plan

GLSE compound

Drug

Maitake mushroom extract compound

Drug

Ginseng compound

Drug

Primary outcomes

  1. T-lymphocyte cell subsets

    Time frame: three mouths

    T-lymphocyte cell subsets contains CD3+、CD4+、CD8+、CD28-、CD28+、CD4+CD25+、HLADR+、HLADR-,measured these cells concentration level

Sponsors and collaborators

Lead sponsor

Chinese PLA General Hospital

Other

Registry information

Official study title

Phase 1 Study of Clinical Nutrition That Research Safty and Efficacy in Lung Neoplasms And Breast Carcinoma

Important dates

Study start
2015
Primary completion
2016
Study completion
2017
First posted
Nov 11, 2015
Registry last updated
Mar 14, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.